Lead Capital Partners’ Post

Going from strength to strength…..

Celebrating 11 Years of Ancillarie: A Journey of Excellence   Today, we mark a significant milestone in the history of Ancillarie as we celebrate 11 years of growth, innovation, and excellence. Our journey from a small startup to a dynamic and globally recognized company has been nothing short of remarkable. As we reflect on this journey, we want to take a moment to express our gratitude to all those who have contributed to our success. Founding Principles: Ancillarie was founded on the principles of innovation, quality, and client-centric service. These principles have guided our path over the years, and they remain the cornerstone of our business. Unwavering Commitment: Our commitment to delivering exceptional services to our clients has never wavered. We've worked tirelessly to develop cutting-edge solutions that meet and exceed the evolving needs of our clients. Strategic Partnerships: Collaboration has been at the heart of our journey. We've fostered strong partnerships with clients, suppliers, and other industry leaders. These relationships have allowed us to thrive and continue our pursuit of excellence. Global Expansion: From our humble beginnings, we've expanded our reach globally. Today, Ancillarie serves clients in diverse markets, and we're proud of the trust they place in us. Innovative Solutions: Innovation is in our DNA. We've consistently pushed the boundaries to develop state-of-the-art solutions that streamline processes, enhance efficiency, and drive success for our clients. Our Team: Our incredible team is the backbone of Ancillarie. Their dedication, expertise, and unwavering commitment to our vision have been instrumental in our journey. We owe our success to them. Client Success: The success of our clients is our ultimate goal. We celebrate each achievement, no matter how big or small, because they are a testament to the quality of our services and the strength of our partnerships. As we enter our 12th year, we do so with renewed vigor and a commitment to continuing our legacy of excellence. The road ahead is filled with exciting opportunities, and we are well-prepared to embrace them. Thank you to our clients, partners, and our exceptional team for making this journey possible. Your trust, support, and dedication have been invaluable. Here's to another year of growth, innovation, and success. Together, we'll continue to reach new heights and set even higher standards in our industry. #team #client #partners #excellence #expansion #quality #clinicaldatamanagement #clincialtrials #medicalwriting #statisticalanalysis #statisticalprogramming

I’ve been asked a lot recently; “what makes MYTHERESA successful in such a challenging space?” The compete answer is not short enough to cover in a caption here, however it’s also not long and overly sophisticated. In 2013 Lawrence Lenihan contributed this to a BOF article by Vikram Alexei Kansara Laurence also told me this face to face in New York a few months earlier. I never forgot it. (Quote in image) At MYTHERESA we never got caught up in chasing distorted, unprofitable growth or complicated business structures. (Key factors behind recent collapses, there are more to come) Throughout all the online hype MYTHERESA remained laser focussed on being the best at no2 and no3 on this list. It has been proven that brands big or small who’s business is not >90% DTC need partners who understand no2 & no3 here, and can deliver it. The landscape is tricky however the future is bright for players such as MYTHERESA and FLANNELS in the UK who are a standout examples of what Laurence refers to in this 2013 article . Michael Kliger - Keep going, but send us back Harry Kane please, it’s hard to explain to my 4 year old son!

Daniel Sheppard and Dave Sheppard, CMAA from @ MedWorld Advisors are at the Association for Corporate Growth (ACG) #DealMax24 today thru Wednesday. Looking forward to meeting with some of the most active PE Firms in Healthcare in 2024 on behalf of our clients. If your business is in #MedTech, #DigitalHealthTech, #Diagnostics, #LifeSciences, #DentalTech and you are thinking of selling (or someone you know is considering it), please feel free to reach out to discuss #Exit Strategy and #Valuation in today's marketplace. #mergersandacquisitions #M&A #medworld #exitstrategy

Today, we achieved a new milestone at Verilo – within just 6 hours of launching our latest business listing, we received an unprecedented 32 expressions of interest. This isn't just a number for us; it's a testament to the enduring appeal and resilience of the healthcare sector. In a time when the M&A market faces turbulence and borrowing challenges are more pronounced, it's heartening to see such robust interest. While not all enquiries will progress to firm offers, a significant number come from serious buyers, many of whom have an established relationship with us. This surge in interest reinforces our belief: the UK healthcare sector continues to be a compelling prospect for investment. It's clear that even in uncertain times, the demand for quality healthcare businesses remains strong. At Verilo, we're committed to connecting these high-potential opportunities with the right investors. #healthcareInvestment #businessforsale

This article from Verilo discusses growth strategies in the therapy sector, focusing on buying businesses as an alternative to organic expansion. It outlines the risks and benefits, practical steps to get started, and considerations for choosing the right business to acquire. The article emphasises the importance of careful planning, research, and professional advice in this process, highlighting the potential for rapid growth and profitability through acquisitions. If you are interested in growing via acquisition, you can read the full article here: https://lnkd.in/eYhfbhhd #growthstrategies #privatepractice #aquisition #buyingabusiness #therapy #therapist

🌟 Mark your calendars for MedTech Malta 📅 Mathieu Horras, our CEO, has been invited to join the panel "The Role of CEO", moderated by the esteemed Malek Nasr, on October 20th at 1:45 pm at the upcoming MedTech Malta Conference. With a strong experience as a CEO and co-founder of Aspivix for over 8 years, Mathieu Horras has an interesting and insightful experience to share as he combines the CEO role focusing on setting the company’s vision and mission with the right talents 💼 , raising capital 💰 , driving innovation 💡 to drive growth 📈 as well as being one of the co-founders 🤝 . The panel promises to be an enriching 45-minute discussion and experience-sharing on the importance of the role of a CEO to drive innovation to success , as well as the challenges a CEO has to overcome from a worldwide group of co-panelists 🌎. 👥 Panelists: Mathieu Horras Youssef Biadillah Amrish Nair Greg Walters  Edo Ceder Tom Lobby Join the #MedTech Malta Conference, which brings investors, visionaries, and entrepreneurs from around the globe together to exchange ideas, network, and explore cutting-edge innovations in the world of MedTech. We’re eagerly looking forward to this insightful panel discussion as well as the #MedTech Malta conference spanning over two days, each packed with engaging talks, inspiring startup showcases a thrilling pitch competition, and networking opportunities. 🔗 For more information, visit: https://lnkd.in/emzaXk2p #MedTechMalta #Conference #MedTech #Networking #CEO #startup #investor #WomensHealth #FemTechRevolution #InnovationForHer #Contraception #IUD #Gynecology #reproductivehealth #femtech #fertility #medtech #clinicaltrial #medicaldevice #technology #health

Melodiol Global Health Ltd (ASX:ME1) is set to raise around $1.4 million in a cash placement and agreements to convert debt to equity. The company has received firm commitments from new and existing institutional, professional and sophisticated investors to raise cash and convert current liabilities to equity through the issue of approximately 167,445,189 fully paid ordinary shares at $0.00821 per share. Melodial will also satisfy its obligations under the third amortisation payment to SBC Global under the Convertible Note Facility via the issuance of 33.75 million shares. Once complete, the facility will be two-thirds repaid. Use of funds The company will use the money raised for marketing and sales initiatives, along with the completion of pending M&A. Importantly, the placement adds to its strong unaudited net sales for the combined Melodiol group of $4.74 million during Q2 FY2023. This is a 105% gain. More at #Proactive #ProactiveInvestors #ASX #ME1 #cannabis #psychedelics #AlternateHealth http://ow.ly/AA2M104QylV

✅ What we do: Partner with the best and grow together. ❌ What we don't do: Gut your company, replace all your employees, and change everything you've built. The model of some P.E. companies is to take a business that ISN'T thriving and increase their profit margin, requiring them to change everything in order to do so. But that's the opposite of what we're doing at Alpha. We partner with med spas that are already doing amazing and let them KEEP doing what's made them successful, providing our expertise and offering guidance in key areas they need to grow. In other words, we help our partners with the things they need support with, and we get to standardize the things they're doing world-class. This is how we become stronger together. 👏🔥 #strongertogether #partnerwithalpha #privateequity #medspa #aesthetics #bestinclass